Transparency Needed for Economic Analyses of PA Programs

Transparency Needed for Economic Analyses of PA Programs Dear Editor, I am writing in response to the article Pharmacoeconomic Modeling of Prior-Authorization Intervention for COX-2 Specific Inhibitors in a 3-Tier Copay Plan in the July/August 2003 issue of the Journal of Managed Care Pharmacy. 1 While the authors are to be commended for using an economic analysis to assess the impact of a prior-authorization (PA) program, I have some objections with the paper that I wish to express. My primary objection addresses the lack of transparency in methods used.